May 12, 2021 -- Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen receptor T-cell (UCART) trials.
Using alemtuzumab in a lymphodepleting regimen should reduce a patient's host immune cells and improve allogeneic CAR T-cell expansion and persistence. UCART T cells are being evaluated for the treatment of relapsed/refractory acute lymphocytic leukemia and relapsed/refractory acute myeloid leukemia.
The companies agreed to execute a commercial supply of alemtuzumab, although financial details were not disclosed.